Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Haemonetics CorpHAE35.163.204.5419.9913.97%3.45%49.88$84.42$338.2914,800$85.54

Detail of Haemonetics Corp

 
CEO
Mr. Christopher A. Simon
Employees
3657
Industry
Medical Instruments & Supplies
Sector
Healthcare
Market cap
$4B

Company details

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$1.36B
Cost of goods (CoG)
-$645.09M
Gross profit (GP)
$716.13M
Operating expense (OE)
-$508.69M
Research and development (R&D)
-$60.10M
General and administrative (G&A)
-$448.59M
Operating income (OI)
$165.37M
Other income expense (OIE)
-$2.00M
Pretax income (PI)
$158.86M
Tax (TAX)
-$35.05M
Net income (NI)
$123.81M
Haemonetics Corp
HAE • XNYS • US
$85.54
+0.40 (0.47%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$2.43
Margin profit
9.10%
52 week low
$70.900002
52 week high
$97.370003
50-day simple moving average
$85.72
200-day simple moving average
$84.42
Percent held by insiders
0.89%
Percent held by institutions
113.72%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
HAE +0.47%
eps change
HAE +34.41%